Compare
Side-by-side on structured fields and reviewer posture.
| Field | Anti-Amyloid Monoclonal (Early AD) | CFTR Corrector Triple Combination | FXN Frataxin Restoration Program |
|---|---|---|---|
| Indication | Alzheimer disease | Cystic fibrosis | Friedreich ataxia |
| Disease area | Neurodegeneration | Pulmonary | Neurodegeneration |
| Modality | Monoclonal antibody | Small molecule | Gene therapy (AAV) |
| Stage | Phase 2 | Phase 3 | IND-enabling |
| Targets | APPMAPT | CFTR | FXN |
| Posture | Mixed· medium conf | Supportive· high conf | Mixed· low conf |
| Reviews | 1 | 1 | 1 |
| Evidence claims | 4 | 3 | 2 |
| Trials | — | NCT00112359NCT01140451 | — |
Comparison uses qualitative posture bands and structured fields — never an averaged rubric score. Select up to 4 assets.